Company: MIRA
Filing Date: 2025-08-08
Form Type: DEFM14A
Source: 0001641172-25-022816
Chunk: 18

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-08
Form: DEFM14A
Chunk 18
---
 for voting your shares, you should contact MIRA at 1200 Brickell Avenue, Suite 1950 #1183, Miami, Florida, (786) 432-9792.

| 5 |

<div align='center'>SUMMARY OF MERGER PROPOSAL</div>

This summary highlights selected information from this proxy statement and may not contain all of the information that is important to you. To better understand the Merger and the proposals being considered at the MIRA Annual Meeting, you should read this entire proxy statement carefully, including the Merger Agreement attached as Annex A, the valuation report of SKNY Pharmaceuticals, Inc. attached as Annex B, the valuation report for MIRA Pharmaceuticals Inc. is attached as Annex C, the fairness opinion for the Merger is attached as Annex D and the SKNY-1 License Agreement is attached as Annex E. For more information, please see the section titled “Where You Can Find More Information” beginning on page 67 of this proxy statement.

The Companies

MIRA Pharmaceuticals, Inc.

1200 Brickell Avenue, Suite 1950 #1183

Miami, Florida

(786) 432-9792

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is a clinical-stage pharmaceutical development company advancing two neuroscience programs targeting neurologic and neuropsychiatric disorders. The company holds exclusive rights in the U.S., Canada, and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in pain management, depression, PTSD and cognitive function.

Ketamir-2: A Novel Oral Ketamine Analog

Ketamir-2 is a patent-pending, oral ketamine analog currently being evaluated for the treatment of diabetic neuropathic pain and is in an ongoing Phase I clinical trial. The compound is designed to overcome the limitations of existing ketamine-based treatments, offering the potential for enhanced safety, improved tolerability, and better oral bioavailability. If approved, Ketamir-2 could provide a safer, more effective option for patients suffering from neuropathic pain, treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDD-SI), and post-traumatic stress disorder (PTSD), with the potential for further clinical development across these and other neuropsychiatric indications..

Neuropathic pain is a complex, chronic condition resulting from damage or dysfunction in the nervous system, leading to abnormal sensations or pain responses. Common symptoms include burning, coldness, “